NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma

por Hao, M, Franqui-Machin, R, Xu, H, Shaughnessy, J, Barlogie, B, Roodman, D, Quelle, D E, Janz, S, Tomasson, M H, Sanderson, R D, Qiu, L, Frech, I, Tricot, G, Zhan, F
Publicado 2017

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR...

por Lesokhin, A. M., Arnulf, B., Niesvizky, R., Mohty, M., Bahlis, N. J., Tomasson, M. H., Rodrίguez-Otero, P., Quach, H., Raje, N. S., Iida, S., Raab, M.-S., Czibere, A., Sullivan, S., Leip, E., Viqueira, A., Leleu, X.
Publicado 2022